Michael Gelband’s NRC Health Common Stock NRC Stock Holding History

Michael Gelband’s Portfolio NRC Stock Details NRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,838	Closed	-$292K	–	1900
2025 Q3	$292K	Buy	+22,838	New	+$343K	﹤0.01%	1314
2025 Q2	–	Sell	-12,786	Closed	-$164K	–	1817
2025 Q1	$164K	Sell	12,786 -8,249	-39%	-$132K	﹤0.01%	1319
2024 Q4	$371K	Buy	21,035 +694	+3%	+$13.2K	﹤0.01%	1227
2024 Q3	$465K	Buy	+20,341	New	+$460K	﹤0.01%	1212
2024 Q2	–	Sell	-15,420	Closed	-$611K	–	1836
2024 Q1	$611K	Buy	15,420 +10,237	+198%	+$405K	﹤0.01%	1093
2023 Q4	$205K	Buy	+5,183	New	+$217K	﹤0.01%	1272
2021 Q4	–	Sell	-11,489	Closed	-$484K	–	2467
2021 Q3	$484K	Sell	11,489 -3,268	-22%	-$165K	0.01%	1418
2021 Q2	$677K	Buy	+14,757	New	+$702K	0.01%	1208
2021 Q1	–	Sell	-9,903	Closed	-$423K	–	2446
2020 Q4	$423K	Buy	+9,903	New	+$508K	﹤0.01%	1347
2019 Q3	–	Sell	-5,125	Closed	-$295K	–	1539
2019 Q2	$295K	Buy	+5,125	New	+$237K	0.01%	704

Other funds holding NRC

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's NRC Position: Q4 2025 in Review

Michael Gelband sold out of NRC Health Common Stock (NRC) in Q4 2025, closing a stake of 22,838 shares — an estimated $292K sold.

Michael Gelband first reported a position in NRC in Q2 2019 and held it in 10 quarters. The position peaked at $677K in Q2 2021. 117 funds tracked by Wall St. Rank hold NRC as of Q4 2025.

Michael Gelband reported no remaining NRC Health Common Stock position as of Q4 2025 after selling out during the quarter.
Michael Gelband sold 22,838 NRC Health Common Stock shares in Q4 2025, an estimated $292K.
Michael Gelband first reported a position in NRC Health Common Stock in Q2 2019 and held it in 10 quarters.
Michael Gelband's NRC Health Common Stock position peaked at $677K in Q2 2021.
117 funds tracked by Wall St. Rank held NRC Health Common Stock as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.